Record Date for Reverse Share Split in Scandinavian Real Heart AB
Kurs
-0,26%
Likviditet
0,07 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-02-26 | 08:30 | Bokslutskommuniké 2024 |
| 2024-11-21 | - | Split HEART 100:1 |
| 2024-11-14 | - | Kvartalsrapport 2024-Q3 |
| 2024-11-05 | - | Extra Bolagsstämma 2024 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-10 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2024-06-07 | - | Årsstämma |
| 2024-05-08 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-15 | - | Bokslutskommuniké 2023 |
| 2023-11-24 | - | Extra Bolagsstämma 2023 |
| 2023-11-16 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-16 | - | Årsstämma |
| 2023-06-15 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2023-06-14 | - | Årsstämma |
| 2023-05-11 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-24 | - | Bokslutskommuniké 2022 |
| 2022-11-18 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-15 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2022-06-14 | - | Årsstämma |
| 2022-05-20 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-08-05 | - | Extra Bolagsstämma 2021 |
| 2021-05-20 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-03 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-19 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-08-04 | - | Extra Bolagsstämma 2020 |
| 2020-05-20 | - | Kvartalsrapport 2020-Q1 |
| 2020-05-19 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2020-05-18 | - | Årsstämma |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-11-21 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-27 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2019-03-26 | - | Årsstämma |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-23 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-24 | - | Årsstämma |
| 2018-05-17 | - | Kvartalsrapport 2018-Q1 |
| 2018-05-11 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-11-27 | - | Extra Bolagsstämma 2017 |
| 2017-11-23 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-31 | - | Kvartalsrapport 2017-Q1 |
| 2017-05-11 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2017-05-10 | - | Årsstämma |
| 2017-02-23 | - | Bokslutskommuniké 2016 |
| 2016-11-24 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-11 | - | Kvartalsrapport 2016-Q1 |
| 2016-05-10 | - | Årsstämma |
| 2016-04-20 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2016-02-18 | - | Bokslutskommuniké 2015 |
| 2015-11-12 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-28 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-26 | - | Kvartalsrapport 2015-Q1 |
| 2015-05-21 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2015-05-20 | - | Årsstämma |
| 2015-02-18 | - | Bokslutskommuniké 2014 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
At the Extraordinary General Meeting in Scandinavian Real Heart AB (“Realheart” or the “Company”) held on 5 November 2024 a reverse share split of 1:100 was resolved upon, whereby one hundred (100) existing shares become one (1) share. Further, the Extraordinary General Meeting resolved to authorize the Board of Directors to determine the record date for the reverse share split. The Board of Directors of Realheart has today resolved that the record date for the reverse split shall be 22 November 2024.
Reverse share split
At the Extraordinary General Meeting in Realheart held on 5 November 2024 a reverse share split of 1:100 was resolved upon, whereby one hundred (100) existing shares become one (1) share. Further, the Extraordinary General Meeting resolved to authorize the Board of Directors to determine the record date for the reverse share split. The Board of Directors of Realheart has today resolved that the record date for the reverse split shall be 22 November 2024.
No action is required by shareholders to participate in the reverse split.
As a consequence of the reverse split, the ISIN Code for the Realheart share will be changed. As from 21 November 2024, the shares will be traded with the new ISIN Code SE0023286836.
The reverse split means that the total number of shares in the Company will be reduced from 206,815,200 shares to 2,068,152 shares, each with a quota value of approximately SEK 5.01. The reverse split will result in a corresponding re-calculation of the outstanding warrants and incentive scheme in Realheart. Shareholders, whose number of shares on the record date is not evenly divided by 100, will for no consideration receive shares from Najar Medical and Invention AB, so that their respective shareholding will be evenly divided by 100. The transfer of these rounding shares will be administrated by Euroclear Sweden AB and without shareholders being required to take any further actions.
Time table for the reverse split
- The last trading date in Realheart’s share before the reverse split shall be 20 November 2024.
- The first trading date in Realheart’s share after the reverse split shall be 21 November 2024, which means that the share price as from this date will reflect the effects of the reverse split.
- The record date for the reverse split shall be Friday 22 November 2024.
For more information, please contact:
Ina Laura Perkins, CEO
Phone: +46 (0) 70 406 49 21
E-mail: inalaura.perkins@realheart.se
Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se
About Us
Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. Realheart® TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trial models ahead of a first clinical study in patients. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se